Vivek Subbiah/LinkedIn
Aug 8, 2025, 15:08
Vivek Subbiah: Engaging Discussion
Vivek Subbiah, Chief of Early-Phase Drug Development at Sarah Cannon Research Institute, shared on LinkedIn:
“Engaging discussion with Saheli Sadanand the amazing Deputy Editor at Nature Medicine
I made the case: This is a terrific time in oncology research. AI is accelerating insights. Precision medicine is personalizing care. Drug development is defying limits. We have challenges in real world implementation.
Journals like Nature, Nature Medicine Nature Magazine must keep leading and prioritizing oncology, amplifying breakthroughs, & shaping the future of care.
Thanks Saheli for listening to my pitch and sharing the vision for Oncology.”
More posts featuring Vivek Subbiah.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 8, 2025, 17:21
Aug 8, 2025, 17:21
Aug 8, 2025, 16:46
Aug 8, 2025, 16:41
Aug 8, 2025, 16:31
Aug 8, 2025, 16:11
Aug 8, 2025, 15:57
Aug 8, 2025, 15:54
Aug 8, 2025, 15:49